Common properties for propargylamines of enhancing superoxide dismutase and catalase activities in the dopaminergic system in the rat: implications for the life prolonging effect of (–)deprenyl

  • K. Kitani
  • C. Minami
  • W. Maruyama
  • S. Kanai
  • G. O. Ivy
  • M.-C. Carrillo
Conference paper


(–)Deprenyl has been reported to prolong the life span of different animal species. Further, the drug effectively increases antioxidant enzyme activities such as superoxide dismutase (SOD) and catalase (CAT) in brain dopaminergic regions. We have found that the effect of the drug on antioxidant enzyme activities is highly dose dependent, increasing with an increasing dose, however, a higher dose becomes less effective and an excessive dose becomes adversely effective. Most importantly, an optimal dose for the effect varies widely depending on animal species, strain, sex, age and duration of the treatment, which may at least partly explain discrepancies reported among different studies in the past. From the parallelism of the dose-effect relationship of the drug between life span extension and increasing endogenous antioxidant enzyme activity, we have suggested that the above two effects of (–)deprenyl may be causally related. This review summarizes our past series of studies and also reports our very recent observation that other propargylamines such as rasagiline and (R)-N-(2-heptyl)-N-methylpropagylamine (R-2HMP) also share the property of enhancing antioxidant enzyme activities. Further, our most recent study has found that these propargylamines increase antioxidant enzyme activities not only in brain dopaminergic regions but in extra-brain dopaminergic tissues such as the heart and kidneys. These observations are discussed in relation to the life prolonging effect of (–)deprenyl reported in the past.


Optimal Dose Antioxidant Enzyme Activity Dopaminergic System Neurobiol Aging Life Span Extension 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Archer JR, Harrison DE (1996) L-deprenyl treatment in aged mice slightly increases life spans, and greatly reduces fecundity by aged males. J Gerontol 31A: B448-B453Google Scholar
  2. Beers RF Jr, Sizer IW (1952) A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem 195: 133-140PubMedGoogle Scholar
  3. Bickford PC, Adams CE, Boyson SJ, Curella P, Gerhardt GA, Heron C, Ivy GO, Lin AMLY, Murphy MP, Poth K, Wallace DR, Young DA, Zahniser NR, Rose GM (1997) Long-term treatment of male F344 rats with deprenyl: Assessment of effects on longevity, behavior, and brain function. Neurobiol Aging 18: 309-318PubMedCrossRefGoogle Scholar
  4. Boulton AA (1999) Symptomatic and neuroprotective properties of the aliphatic propargylamines. Mech Ageing Dev 111: 187-195CrossRefGoogle Scholar
  5. Boulton AA, Davis BA, Durden DA, Dyck LE, Juorio AV, Li XM, Paterson IA, Yu PH (1997) Aliphatic propargylamines: new antiapoptotic drugs. Drug Dev Res 42: 150-156CrossRefGoogle Scholar
  6. Burek JD (1978) Pathology of aging rodents. CRC Press, West Palm BeachGoogle Scholar
  7. Carrillo MC, Kanai S, Nokubo M, Kitani K (1991) Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 48: 517-521PubMedCrossRefGoogle Scholar
  8. Carrillo MC, Kanai S, Nokubo M, Ivy GO, Sato Y, Kitani K (1992a) Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat. Exp Neurol 116: 286-294CrossRefGoogle Scholar
  9. Carrillo MC, Kanai S, Sato Y, Ivy GO, Kitani K (1992b) Sequential changes in activities of superoxide dismutase and catalase in brain regions and liver during (–)deprenyl infusion in female rats. Biochem Pharmacol 44: 2185-2189CrossRefGoogle Scholar
  10. Carrillo MC, Kitani K, Kanai S, Sato Y, Ivy GO (1992c) The ability of (–)deprenyl to increase superoxide dismutase activities in the rat is tissue and brain region selective. Life Sci 50: 1985-1992CrossRefGoogle Scholar
  11. Carrillo MC, Kanai S, Sato Y, Nokubo M, Ivy GO, Kitani K (1993) The optimal dosage of (–)deprenyl for increasing superoxide dismutase activities in several brain regions decreases with age in male Fischer 344 rats. Life Sci 52: 1925-1934PubMedCrossRefGoogle Scholar
  12. Carrillo MC, Kitani K, Kanai S, Sato Y, Miyasaka K, Ivy GO (1994a) The effect of a long term (6 months) treatment with (–)deprenyl on antioxidant enzyme activities in selective brain regions in old female F-344 rats. Biochem Pharmacol 47: 1333-1338CrossRefGoogle Scholar
  13. Carrillo MC, Milgram NW, Wu P, Ivy GO, Kitani K (1994b) (–)Deprenyl increases activities of superoxide dismutase (SOD) in striatum of dog brain. Life Sci 54: 1483-1489CrossRefGoogle Scholar
  14. Carrillo MC, Kitani K, Kanai S, Sato Y, Ivy GO, Miyasaka K (1996) Long term treatment with (–)deprenyl reduces the optimal dose as well as the effective dose range for increasing antioxidant enzyme activities in old mouse brain. Life Sci 59: 1047-1057PubMedCrossRefGoogle Scholar
  15. Carrillo MC, Kanai S, Kitani K, Ivy GO (2000a) A high dose of long term treatment with deprenyl loses its effect on antioxidant enzyme activities as well as on survivals of Fischer-344 rats. Life Sci (in press)Google Scholar
  16. Carrillo MC, Minami C, Kitani K, Maruyama W, Ohashi K, Yamamoto T, Naoi M, Kanai S, Youdim MBH (2000b) Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 67: 577-585CrossRefGoogle Scholar
  17. Elstner EF, Heupel A (1976) Inhibition of nitrite formation from hydroxylammon- iumchloride: a simple assay for superoxide dismutase. Anal Biochem 70: 66-620CrossRefGoogle Scholar
  18. Finberg JPM, Takashima T, Johnston JM, Commissiong JW (1998) Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuro Rep 9: 703-707Google Scholar
  19. Freisleben HJ, Neeb A, Lehr F, Ackermann H (1997) Influence of Selegiline and lipoic acid in the life expectancy of immunosuppressed mice. Arzneim-Forsch 47: 776-780Google Scholar
  20. Fujita S, Kitagawa H, Chiba M, Suzuki T, Ohta M, Kitani K (1985) Age and sex associated differences in the relative abundance of multiple species of cytochrome P-450 in rat liver microsomes – a separation by HPLC of hepatic microsomal cytochrome P-450 species. Biochem Pharmacol 34: 1861-1864PubMedCrossRefGoogle Scholar
  21. Gallagher IM, Clow A, Glover V (1998) Long term administration of (-)deprenyl increases mortality in male Wistar rats. J Neural Transm Suppl 52: 315-320PubMedCrossRefGoogle Scholar
  22. Gallagher IM, Clow A, Jenner P, Glover V (1999) Effect of long-term administration of pergolide and (-)deprenyl on age related decline in hole board activity and antioxidant enzymes in rats. Biogenic Amines 15: 379-393Google Scholar
  23. Ingram DK, Wiener HL, Chachich ME, Long JM, Hengemihle J, Gupta M (1993) Chronic treatment of aged mice with L-deprenyl produces marked MAO-B inhibition but no beneficial effects on survival, motor performance, or nigral lipofuscin accumulation. Neurobiol Aging 14: 431-440PubMedCrossRefGoogle Scholar
  24. Kamataki T, Maeda K, Shimada M, Kitani K, Nagai T, Kato R (1985) Age-related alteration in the activities of drug-metabolizing enzymes and contents of sex-specific forms of cytochrome P-450 in liver microsomes from male and female rats. J Pharmacol Exp Ther 233: 222-228PubMedGoogle Scholar
  25. Kitani K (1988) Drugs and the ageing liver. Life Chem Rep 6: 143-230Google Scholar
  26. Kitani K, Kanai S, Sato Y, Ohta M, Ivy GO, Carrillo MC (1993) Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats: further evidence. Life Sci 52: 281-288PubMedCrossRefGoogle Scholar
  27. Kitani K, Miyasaka K, Kanai S, Carrillo MC, Ivy GO (1996) Upregulation of antioxidant enzyme activities by deprenyl: implications for life span extension. Ann N Y Acad Sci 786: 391-409PubMedCrossRefGoogle Scholar
  28. Kitani K, Kanai S, Ivy GO, Carrillo MC (1998a) Assessing the effects of deprenyl on longevity and antioxidant defences in different animal models. Ann N Y Acad Sci 854: 291-306CrossRefGoogle Scholar
  29. Kitani K, Tanaka S, Zs.-Nagy I (1998b) Age-dependence of the lateral diffusion coefficient of lipids and proteins in the hepatocyte plasma membrane of BN/Bi RijHsd rats as revealed by the smear FRAP technique. Arch Gerontol Geriatr 26: 257-273CrossRefGoogle Scholar
  30. Kitani K, Kanai S, Ivy GO, Carrillo MC (1999) Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effect of deprenyl: a possible antioxidant strategy. Mech Ageing Dev 111: 211-221PubMedCrossRefGoogle Scholar
  31. Knoll J (1988) The striatal dopamine dependency of life span in male rats: longevity study with (-)deprenyl. Mech Ageing Dev 46: 237-262PubMedCrossRefGoogle Scholar
  32. Knoll J (1989) The pharmacology of selegiline/(-)deprenyl. New aspects. Acta Neurol Scand 126: 83-91CrossRefGoogle Scholar
  33. Knoll J, Dallo J, Yen TT (1989) Striatal dopamine, sexual activity and life span. Longevity of rats treated with (-)deprenyl. Life Sci 45: 525-531PubMedCrossRefGoogle Scholar
  34. Knollema S, Aukema W, Hom H, Korf J, Horst GJT (1995) L-Deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia. Stroke 26: 1883-1887PubMedCrossRefGoogle Scholar
  35. Kontkanen O, Castren E (1999) Trophic effects of selegiline on cultured dopaminergic neurons. Brain Res 829: 190-192PubMedCrossRefGoogle Scholar
  36. Li X-M, Juorio AV, Qi J, Boulton AA (1998) L-deprenyl potentiates NGF-induced changes in superoxide dismutase mRNA in PC12 cells. J Neurosci Res 53: 235-238PubMedCrossRefGoogle Scholar
  37. Lowry OH, Rosenbrough MJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275PubMedGoogle Scholar
  38. Maruyama W, Naoi M (1999) Neuroprotection by (-)deprenyl and related compounds. Mech Ageing Dev 111: 189-200PubMedCrossRefGoogle Scholar
  39. McCord EF, Friedovich I (1969) Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 244: 6049-6055PubMedGoogle Scholar
  40. Milgram NW, Racine RJ, Nellis P, Mendonca A, Ivy GO (1990) Maintenance of L-deprenyl prolongs life in aged male rats. Life Sci 47: 415-420PubMedCrossRefGoogle Scholar
  41. Müller T, Kuhn W, Krüger R, Przuntek (1998) Selegiline as immunostimulant – a novel mechanism of action? J Neural Transm Suppl 52: 321-328PubMedCrossRefGoogle Scholar
  42. Nokubo M (1985) Physical-chemical and biochemical differences in liver plasma membranes in aging F-344 rats. J Gerontol 40: 409-414PubMedCrossRefGoogle Scholar
  43. Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70: 158-169PubMedGoogle Scholar
  44. Piantanelli L, Zaia A, Rossolini G, Vitiechi C, Testa R, Basso A, Antognini A (1994) Influence of L-deprenyl treatment on mouse survival kinetics. In: Zs-Nagy I, Harman D, Kitani K (eds) Pharmacology of aging processes. Method of assessment and potential interventions. Ann N Y Acad Sci 717: 72-78Google Scholar
  45. Ruehl WW, Bice D, Muggenburg B, Bruyette DD, Stevens DR (1994) L-Deprenyl and canine longevity: Evidence for an immune mechanism, and implications for human aging. 2nd Conference on Anti-Aging Medicine, Las Vegas, Abstract 25-26Google Scholar
  46. Ruehl WW, Entriken TL, Muggenburg BA, Bruyette DS, Griffith WG, Hahn FF (1997) Treatment with L-deprenyl prolongs life in elderly dogs. Life Sci 61: 1037-1044PubMedCrossRefGoogle Scholar
  47. Stoll S, Hafner U, Kraenzlin B, Mueller WE (1997) Chronic treatment of Syrian hamsters with low-dose selegiline increases life span in females but not males. Neurobiol Aging 18: 205-211PubMedCrossRefGoogle Scholar
  48. Strolin BM, Keane PE (1980) Differential changes in monoamine oxidase-A and -B activity in the aging rat brain. J Neurochem 35: 1026-1032CrossRefGoogle Scholar
  49. Tang YP, Ma YL, Chao CC, Chen KY, Lee EHY (1998) Enhanced glial cell line-derived neurotrophic factor mRNA expression upon (-)deprenyl and melatonin treatments. J Neurosci Res 53: 593-604PubMedCrossRefGoogle Scholar
  50. ThyagaRajan S, Quadri SK (1999) L-deprenyl inhibits tumor growth, reduces serum prolactin, and suppresses brain monoamine metabolism in rats with carcinogen-induced mammary tumors. Endocrine 10: 225-232PubMedCrossRefGoogle Scholar
  51. ThyagaRajan S, Meites J, Auadri SK (1995) Deprenyl reinitiates estrous cycles, reduces serum prolactin, and decreases the incidence of mammary and pituitary tumors in old acyclic rats. Endocrinology 136: 1103-1110.PubMedCrossRefGoogle Scholar
  52. ThyagaRajan S, Felten SY, Felten DL (1998) Antitumor effect of L-deprenyl in rats with carcinogen-induced mammary tumors. Cancer Lett 123: 177-183PubMedCrossRefGoogle Scholar
  53. ThyagaRajan S, Madden KS, Stevens SY, Felten DL (1999) Effects of L-deprenyl treatment on noradrenergic innervation and immune reactivity in lymphoid organs of young F-344 rats. J Neuroimmunology 96: 57-65CrossRefGoogle Scholar
  54. Yoshida T, Oguro T, Kuroiwa Y (1987) Hepatic and extrahepatic metabolism of deprenyl, a selective monoamine oxidase (MAO)B inhibitor of amphetamines in rats: sex and strain differences. Xenobiotica 8: 957-963CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2000

Authors and Affiliations

  • K. Kitani
    • 1
  • C. Minami
    • 1
  • W. Maruyama
    • 1
  • S. Kanai
    • 2
  • G. O. Ivy
    • 3
  • M.-C. Carrillo
    • 4
  1. 1.National Institute for Longevity SciencesAichiJapan
  2. 2.Tokyo Metropolitan Institute of GerontologyTokyoJapan
  3. 3.Life Science DivisionUniversity of TorontoScarboroughCanada
  4. 4.National University of RosarioRosarioArgentina

Personalised recommendations